Moderna Inc (MRNA) — Cash Flow-to-Debt Ratio
Moderna Inc (MRNA) has a Cash Flow-to-Debt Ratio of -0.13x as of June 2026, meaning its operating cash flow of $-526.00 Million could theoretically repay 0% of its total liabilities ($4.20 Billion) in one year. See MRNA FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Moderna Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Moderna Inc across 12 annual periods. For the full cash flow conversion analysis, see Moderna Inc cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Moderna Inc (2014–2025)
Year-by-year debt coverage analysis for Moderna Inc. Check earnings quality score of Moderna Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.51x | $-1.87 Billion | $3.69 Billion | ▲ +45.2% |
| 2024 | -0.93x | $-3.00 Billion | $3.24 Billion | ▼ -35.9% |
| 2023 | -0.68x | $-3.12 Billion | $4.57 Billion | ▼ -192.2% |
| 2022 | 0.74x | $4.98 Billion | $6.74 Billion | ▼ -42.9% |
| 2021 | 1.29x | $13.62 Billion | $10.52 Billion | ▲ +204.9% |
| 2020 | 0.42x | $2.03 Billion | $4.78 Billion | ▲ +138.3% |
| 2019 | -1.11x | $-458.97 Million | $414.61 Million | ▼ -44.5% |
| 2018 | -0.77x | $-330.87 Million | $431.91 Million | ▼ -6.1% |
| 2017 | -0.72x | $-331.48 Million | $459.19 Million | ▼ -722.3% |
| 2016 | 0.12x | $66.73 Million | $575.31 Million | ▲ +102.7% |
| 2015 | -4.30x | $-738.15K | $171.66K | ▼ -1122.5% |
| 2014 | -0.35x | $-4.78 Million | $13.59 Million | — |